Krishna Institute of Medical Sciences Ltd (KIMS) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company achieved a record-breaking quarter, with revenue surpassing the INR 1,000 crore mark for the first time, demonstrating strong growth despite Q3 traditionally being a weaker period.
- Overall performance was driven by robust growth in newer units and a strong showing from the Telangana cluster, although profitability was impacted by the initial operational costs and EBITDA erosion from newly commissioned hospitals.
- The company has made significant clinical achievements, including over 100 lung transplants, 430 renal transplants, and 120 liver transplants across the group in 2025, reinforcing its clinical excellence and expansion into complex procedures.
- Strategic expansion continues with the launch of seven new hospitals in 2025 across multiple states and a new agreement to construct a hospital in Chennai, marking its entry into the Tamil Nadu market.
- Management expressed confidence in the stabilization of new units, expecting them to turn EBITDA positive in the upcoming quarters and contribute significantly to future growth, with a clear focus on achieving break-even before further operationalizing bed capacity.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.